The lysine-specific demethylase 1 (LSD1) is overexpressed in several cancers including rhabdomyosarcoma (RMS). However, little is yet known about whether or not LSD1 may serve as therapeutic target in RMS. We therefore investigated the potential of LSD1 inhibitors alone or in combination with other epigenetic modifiers such as histone deacetylase (HDAC) inhibitors. Here, we identify a synergistic interaction of LSD1 inhibitors (i.e., GSK690, Ex917) and HDAC inhibitors (i.e., JNJ-26481585, SAHA) to induce cell death in RMS cells. By comparison, LSD1 inhibitors as single agents exhibit little cytotoxicity against RMS cells. Mechanistically, GSK690 acts in concert with JNJ-26481585 to upregulate mRNA levels of the proapoptotic BH3-only proteins BMF, PUMA, BIM and NOXA. This increase in mRNA levels is accompanied by a corresponding upregulation of BMF, PUMA, BIM and NOXA protein levels. Importantly, individual knockdown of either BMF, BIM or NOXA significantly reduces GSK690/JNJ-26481585-mediated cell death. Similarly, genetic silencing of BAK significantly rescues cell death upon GSK690/JNJ-26481585 cotreatment. Also, overexpression of antiapoptotic BCL-2 or MCL-1 significantly protects RMS cells from GSK690/JNJ-26481585-induced cell death. Furthermore, GSK690 acts in concert with JNJ-26481585 to increase activation of caspase-9 and -3. Consistently, addition of the pan-caspase inhibitor N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone (zVAD.fmk) significantly reduces GSK690/JNJ--26481585-mediated cell death. In conclusion, concomitant LSD1 and HDAC inhibition synergistically induces cell death in RMS cells by shifting the ratio of pro-and antiapoptotic BCL-2 proteins in favor of apoptosis, thereby engaging the intrinsic apoptotic pathway. This indicates that combined treatment with LSD1 and HDAC inhibitors is a promising new therapeutic approach in RMS.
RMS represents the most frequent soft-tissue sarcoma in children and comprises two major subtypes, that is, embryonal RMS (eRMS) and alveolar RMS (aRMS). [1] [2] [3] Despite multimodal therapy consisting of surgery, chemotherapy and radiation, the overall survival for patients with advanced disease is still very poor. 4 This highlights the urgent medical need for innovative treatment concepts.
The antineoplastic activity of chemo-, immuno-, or radiotherapy largely depends on the induction of programmed cell death in tumor cells. 5 Apoptosis is one of the most extensively studied forms of programmed cell death that is highly conserved throughout evolution and typically disturbed in cancer cells. 6 Two key signaling pathways to apoptotic cell death have been delineated, namely the intrinsic (mitochondrial) and the extrinsic (death-receptor) pathway, which both eventually lead to activation of caspases. 5, 7 Within the intrinsic pathway, pro-and antiapoptotic proteins of the BCL-2 family control outer mitochondrial membrane permeabilization (MOMP). 7, 8 A shift towards proapoptotic BCL-2 family proteins favors MOMP, followed by the release of cytochrome C and second mitochondria-derived activator of caspases (Smac) from the mitochondrial intermembrane space into the cytosol. 7, 8 Cytochrome C initiates formation of the apoptosome and activation of initiator caspase-9 which in turn activates caspase-3, eventually leading to the execution of apoptotic cell death. 9 Smac contributes to the activation of caspases as it binds to and thereby antagonizes XIAP, a member of the Inhibitor of Apoptosis family of proteins. 10 Post-translational modifications of histone proteins such as acetylation, methylation or phosphorylation create a histone code, which provides the basis for the transcriptional activity of numerous genes. 11, 12 Removal of histone acetylation and demethylation of H3K4 reduce transcriptional activity and are conducted by repressor complexes, like the CoREST complex that contains HDAC1 or HDAC2, as well as LSD1. [13] [14] [15] [16] HDACs have been implicated in contributing to oncogenesis by silencing tumor suppressor genes and apoptosis inducers. 17, 18 LSD1 is known as a regulator of a wide spectrum of biological processes including pluripotency, differentiation, metabolic processes, as well as cancer development and progression. [19] [20] [21] In RMS, HDAC inhibition has been shown to reverse oncogenic features and induce cell death. [22] [23] [24] In recent years, a broad range of inhibitors of epigenetic modifiers has been developed. JNJ-26481585 (Quisinostat) is a second-generation HDAC inhibitor that blocks class I and II HDACs with high potency. 25 1 LSD1 inhibition was first described for the antidepressant agent Tranylcypromine, a MAO-A and MAO-B inhibitor that also inhibits LSD1 due to the high similarity of the catalytic sites of LSD1, MAO-A and MAO-B. 26 In recent years, more specific LSD1 inhibitors have been developed, some of which have already progressed to clinical trials for the treatment of leukemia or lung cancer. 27, 28 High LSD1 levels have been detected in several types of solid tumors or hematological malignancies and have been associated with poor prognosis. 19 Recently, LSD1 has also been shown to be overexpressed in primary RMS samples. 29, 30 However, little is yet known about whether or not LSD1 may serve as a therapeutic target in RMS. Therefore, the current study aims at investigating the potential of LSD1 inhibition in RMS cells, either alone or in combination with other epigenetic modifiers such as HDAC inhibitors.
Results

LSD1
and HDAC inhibitors synergize to induce cell death in RMS cells. To investigate the therapeutic potential of LSD1 inhibition in RMS, we tested the effects of the reversible LSD1 inhibitor GSK690 alone and in combination with the second-generation HDAC inhibitor JNJ-26481585 in RMS cell lines, which represent eRMS (RD, TE381.T) and aRMS (RH30, RMS13) as the two major histological subtypes. Treatment with GSK690 alone had no or little effect on the induction of cell death, as measured by DNA fragmentation, a typical parameter of apoptotic cell death (Figure 1a) , and by propidium iodide (PI) staining ( Supplementary Fig. 1A ). Importantly, GSK690 acted together with JNJ-26481585 to induce cell death in all four tested RMS cells lines (Figure 1a , Supplementary Fig. 1A, 1B) . Calculation of combination index (CI) revealed that the interaction of both agents is synergistic (Supplementary Table 1 ). To investigate whether this synergy extends to other LSD1 and HDAC inhibitors, we used the LSD1 inhibitor Ex917 and the HDAC inhibitor SAHA. Similarly, Ex917 plus JNJ-26481585 as well as SAHA plus GSK690 acted in concert to trigger cell death, whereas treatment with LSD1 inhibitors alone induced basically no cell death ( Supplementary Fig. 1C, 1D) . Also, GSK690 and JNJ-26481585 cooperated to reduce cell viability (Figure 1b ). Assessment after 120 h of exposure to GSK690 and JNJ-26481585 showed profound suppression of cell viability over prolonged time ( Supplementary Fig. 1E ). Treatment with Ex917 alone at the tested concentrations did not affect cell viability and GSK690 decreased cell viability only at high concentrations ( Supplementary Fig. 2A, 2B) . Furthermore, the addition of GSK690 further enhanced the JNJ-26481585-stimulated G2/M arrest ( Supplementary Fig. 3 ).
To assess whether inhibition of LSD1 alters sensitivity of non-malignant cells to HDAC inhibitors we extended our experiments to the murine myoblast cell line C2C12. Treatment with different combinations of LSD1 and HDAC inhibitors at the same concentrations used for RMS cells (i.e., GSK690/ JNJ-26481585, Ex917/JNJ-26481585 or GSK690/SAHA) induced no or little (o 20%) cell death in C2C12 cells ( Supplementary Fig. 4A-C) , thus pointing to some tumor selectivity. Monitoring the kinetics of cell death induction showed that GSK690 significantly increased JNJ-26481585-induced cell death in a time-dependent manner ( Figure 1c) . Control experiments confirmed that LSD1 and HDAC inhibitors caused their typical target-specific effects on histonemodifying enzymes, that is, increased H3K4me2 by LSD1 inhibitors and enhanced histone acetylation by HDAC inhibitors ( Supplementary Fig. 5A , 5B). At an early time point, the addition of GSK690 enhanced the JNJ-26481585-stimulated acetylation of histone H3 ( Supplementary Fig.  5C ), indicating that both drugs cooperate at the histone level. Together, this set of experiments demonstrates that LSD1 and HDAC inhibitors synergize to induce cell death in RMS cells.
GSK690/JNJ-26481585 cotreatment induces caspasedependent cell death. To gain insights into the molecular mechanisms of apoptotic cell death upon treatment with GSK690 and JNJ-26481585, we investigated caspase cleavage as an indicator of caspase activation. GSK690 and JNJ-26481585 cooperated to induce cleavage of the initiator caspase-9 into its active p35 and p37 fragments and of the effector caspase-3 into its active p12 and p17 fragments ( Figure  2a ). Moreover, GSK690 and JNJ-26481585 acted together to cleave poly ADP-ribose polymerase (PARP), a known substrate of caspase-3 ( Figure 2a ). To investigate whether caspase activity is necessary for cell death induction, we used the pancaspase inhibitor zVAD.fmk. Addition of zVAD.fmk significantly reduced GSK690/JNJ-26481585-induced cell death ( Figure 2b) . A kinetic analysis showed that zVAD.fmk almost completely rescued GSK690/JNJ-26481585-conferred cell death at earlier time points in RH30 cells and also significantly protected RD cells at all tested time points (Supplementary. Fig. 6A ). Furthermore, we used the RIP1 kinase inhibitor Necrostatin-1 to explore whether RIP1 is required for cell death. However, addition of Necrostatin-1 failed to rescue cells from GSK690/JNJ-26481585-induced cell death ( Supplementary Fig. 6B ). Altogether, these findings demonstrate that GSK690/JNJ-26481585 cotreatment induces caspase-dependent cell death.
GSK690/JNJ-26481585 cotreatment alters the balance between pro-and antiapoptotic proteins. As both GSK690 and JNJ-26481585 can alter histone modifications towards more active transcriptional sites, we next explored whether GSK690/JNJ-26481585 cotreatment alters mRNA expression of proapoptotic BCL-2 family proteins. Importantly, GSK690/JNJ-26481585 cotreatment stimulated upregulation of BMF and PUMA mRNA levels in both cell lines (Figures 3a and d) prior to the onset of cell death (Figure 1c ). In addition, GSK690 cooperated with JNJ-26481585 to increase BIM mRNA levels in RD cells and NOXA mRNA levels in RH30 cells (Figures 3b and c) .
To determine whether these changes in mRNA levels result in elevated protein expression, we performed Western blotting.
Notably, combination of GSK690 plus JNJ-26481585 upregulated BMF and PUMA protein in both cell lines (Figures 3e and f) . Also, the combination treatment enhanced BIM expression in RD cells and NOXA expression in RH30 cells (Figure 3e ), corresponding to the GSK690/ JNJ-26481585-stimulated increase in their mRNA levels (Figures 3a-c) . It is interesting to note that NOXA was upregulated by GSK690/JNJ-26481585 treatment in RH30 cells, which harbor much lower basal NOXA protein levels than RD cells, while BIM expression was increased by GSK690/ JNJ-26481585 treatment in RD cells that exhibit lower constitutive BIM protein levels compared to RH30 cells ( Supplementary Fig. 7A ). By comparison, protein levels of BCL-2, BCL-x L , and MCL-1 remained largely unchanged upon GSK690/JNJ-26481585 cotreatment ( Supplementary Fig. 7B ).
Together, this set of experiments shows that prior to the onset of cell death GSK690/JNJ-26481585 cotreatment upregulates proapoptotic BH3-only proteins and thus changes the ratio of pro-and antiapoptotic BCL-2 family proteins towards apoptosis.
BMF, BIM, and NOXA contribute to GSK690/JNJ--26481585-induced apoptosis. To test the functional relevance of the observed changes in proapoptotic BH3-only proteins for the induction of apoptosis, we individually silenced BMF, BIM, or NOXA using two distinct siRNA sequences. Control experiments confirmed efficient knockdown of target genes (Figures 4a, c, e) . Importantly, knockdown of either BMF, BIM or NOXA significantly rescued both RD and RH30 cells from GSK690/JNJ-26481585-triggered cell death (Figures 4b, d, f) . These findings indicate that BMF, BIM and NOXA contribute to GSK690/JNJ-26481585-mediated cell death.
BAK contributes to GSK690/JNJ-26481585-induced apoptosis. As BAK, a multi-domain proapoptotic BCL-2 family protein, plays an important role in mediating mitochondrial apoptosis, 31 we next silenced BAK to test the requirement of an intact intrinsic pathway. Western blotting confirmed efficient silencing of BAK by two distinct siRNA sequences (Figure 5a) . Notably, knockdown of BAK significantly rescued both RMS cell lines from GSK690/JNJ-26481585-induced cell death (Figure 5b ). This shows that BAK contributes to GSK690/JNJ-26481585-induced apoptosis.
Overexpression of BCL-2 or MCL-1 reduces GSK690/ JNJ-26481585-induced apoptosis. To further examine the involvement of the mitochondrial pathway in GSK690/JNJ--26481585-induced apoptosis, we overexpressed murine BCL-2 (mBCL-2), as confirmed by Western blotting (Figure 6e ). These findings demonstrate that BCL-2 and MCL-1 inhibit GSK690/JNJ-26481585-induced cell death, emphasizing the role of the mitochondrial pathway in this model of cell death.
Discussion
In recent years, there has been a growing interest in targeting epigenetic modifiers for cancer therapy. Overexpression of the histone demethylase LSD1 frequently occurs in cancer 19 and
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Cotargeting of LSD1 and HDAC in RMS T Haydn et al high LSD1 levels were recently reported in primary RMS samples. 29, 30 Therefore, we investigated the potential of pharmacological LSD1 inhibitors as cancer therapeutics alone and in combination with HDAC inhibitors. Here, we identify a synergism of HDAC inhibitors (i.e., JNJ-26481585, SAHA) and LSD1 inhibitors (i.e., GSK690, Ex917) to induce cell death in RMS cells. In contrast, LSD1 inhibitors as single agents proved to be insufficient for cell death induction in RMS cells, underscoring the relevance of cotargeting epigenetic modifiers for the treatment of RMS. Combined LSD1 and HDAC inhibition exhibits some tumor selectivity, as LSD1 and HDAC inhibitors show no or little cytotoxicity against murine myoblasts at concentrations that potently trigger cell death in RMS cells.
Furthermore, we provide novel insights into the molecular mechanisms underlying this synergism of concomitant LSD1 and HDAC inhibition. We show that GSK690 and JNJ-26481585 act together to induce intrinsic apoptosis by changing the ratio of pro-and antiapoptotic BCL-2 proteins in favor of apoptosis. This conclusion is supported by several independent lines of evidence.
First, GSK690 and JNJ-26481585 cooperate to transcriptionally upregulate several proapoptotic BH3-only proteins, that is, BMF, PUMA and NOXA or BIM, which is accompanied by increased protein levels. The overall shift towards proapoptotic BH3-only proteins is likely to be critical for the synergistic induction of cell death, as the portfolio of individual BH3-only proteins that is increased by GSK690/JNJ--26481585 cotreatment varies between the investigated cell lines. While the combination treatment increases BMF and PUMA expression in both RMS cell lines, BIM and NOXA are upregulated in addition to BMF in RD and RH30 cells, respectively. Upregulation of BMF, PUMA, BIM, and NOXA might well be a direct effect of GSK690/JNJ-26481585-stimulated chromatin modulation, since their mRNA levels increase already early (4 h) after cotreatment. Second, GSK690/ JNJ-26481585-stimulated upregulation of proapoptotic BH3-only proteins is required for cell death induction, since individual silencing of BMF, BIM or NOXA significantly reduces GSK690/JNJ-26481585-mediated cell death. The fact that GSK690/JNJ-26481585-induced cell death does not depend on a single BH3-only protein further underlines the importance of the overall shift towards proapoptotic BH3-only proteins. Third, knockdown of BAK as a direct regulator of MOMP significantly protects from GSK690/JNJ-26481585-induced Synergistic induction of cell death by LSD1 and HDAC inhibitors has previously been described for glioblastoma, 32, 33 AML 34 and breast cancer. 35, 36 Our study not only reveals a synergism of concomitant LSD1 and HDAC inhibition in RMS, but -more importantly -elucidates the molecular mechanisms underlying this synergistic induction of cell death. We show for the first time that GSK690/JNJ-26481585 cotreatment induces intrinsic apoptosis by shifting the balance towards proapoptotic BCL-2 proteins. While the combination of LSD1 knockdown and SAHA treatment has previously been reported to downregulate BCL-2 expression and to increase BAX levels, the functional relevance of these changes for the combination-induced cell death has, however, remained obscure. 36 Furthermore, in the present study we demonstrate synergistic tumor cell death using specific LSD1 inhibitors such as GSK690 and Ex917, whereas most previous combination studies were conducted with Tranylcypromine or Pargyline, 32, 33, 35, 36 which are unspecific LSD1 inhibitors that mainly target MAO-A and/or MAO-B. 26 HDAC inhibitors as single agents have previously been reported to engage intrinsic apoptosis by increasing proapoptotic proteins. 37, 38 In RMS, we previously demonstrated that JNJ-26481585 as single agent at cytotoxic concentrations exerts potent antitumor activity in vitro and in vivo by engaging mitochondrial apoptosis. 39 Also, we showed that subtoxic doses of JNJ-26481585 sensitize RMS cells towards several common chemotherapeutics by enhancing apoptosis via the intrinsic pathway. 40 In the present study, we show that combined inhibition of histone demethylation and deacetylation upregulates proapoptotic BH3-only proteins, indicating that histone demethylation by LSD1 acts in concert with histone deacetylation by HDACs to repress active transcription in RMS cells. Consistently, LSD1 is part of the corepressor complex CoREST, containing also HDAC1 and 2, which augment the gene repressor activity of LSD1. [13] [14] [15] [16] Our study highlights LSD1 as an epigenetic drug target for RMS. While high LSD1 levels have previously been described in patient-derived RMS samples, 29, 30 the functional relevance of LSD1 as a therapeutic target in RMS has remained largely unknown. By demonstrating that specific LSD1 inhibitors synergize with HDAC inhibitors to induce RMS cell death, our study has important implications for the development of novel approaches for epigenetic therapy of RMS. Thus, concomitant targeting of epigenetic modifiers using LSD1 and HDAC inhibitors represents a promising new strategy for the treatment of RMS that warrants further investigation. 1 mM sodium pyruvate (Invitrogen, Heidelberg, Germany). The caspase inhibitor zVAD.fmk was purchased from Bachem (Heidelberg, Germany), Necrostatin-1 from Biomol (Hamburg, Germany), JNJ-26481585 and SAHA (Vorinostat) from Selleck Chemicals (Houston, TX, USA). LSD1 inhibitors GSK690 41, 42 and Ex0000917 were kindly provided by GlaxoSmithKline and Roche, respectively. Chemicals were purchased from Sigma-Aldrich (Taufkirchen, Germany) or Carl Roth (Karlsruhe, Germany) unless otherwise indicated.
Determination of cell viability and cell death. Cell viability was assessed by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay according to the manufacturer's instructions (Roche Diagnostics, Mannheim, Germany). Cell death was measured by flow cytometric analysis (FACS Canto II, BD Biosciences, Heidelberg, Germany) of DNA fragmentation of PI-stained nuclei as described before 43 or by fluorescence-based microscope analysis of PI uptake using Hoechst 33342 and PI double staining (both Sigma-Aldrich) and ImageXpress Micro XLS Widefield High-Content Analysis System and MetaXpress Software according to the manufacturer's instructions (Molecular Devices Sunnyvale, CA, USA).
Transduction. For BCL-2 overexpression, Phoenix packaging cells were transfected with 20 μg of murine stem cell virus (pMSCV, Clontech, Mountain View, CA, USA) vector containing murine BCL-2 (mBCL-2) or EV using calcium phosphate transfection as described previously. 39 Stable cell lines were generated by lentiviral transduction and selected with 10 μg/ml Blasticidin (Invitrogen). For MCL-1 overexpression, cells were transfected with 20 μg of pCMV-Tag3B plasmids, kindly provided by Genentech Inc. (South San Francisco, CA, USA), containing EV, wild-type MCL-1 (WT), or phospho-mutant MCL-1 (4A) using Lipofectamine 2000 (Life Technologies, Inc.) and selected with 0.5 mg/ml G418 (Carl Roth).
